London, ON – January 14th, 2019 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced successfully completing enrollment ahead of the Australian biotech’s corporate milestone target on their Phase 1b Open label study in Uveal Melanoma metastatic to liver.
The last patient was screened in December 2018, and we have now successfully enrolled our final patient into the study. “The Stiris team have worked tirelessly with the three investigative sites to complete enrollment on this complex trial. We are always pleased when we exceed the client’s expectations, allowing them to expedite the trial timelines overall,” said Amanda Carrera, Vice President. “We always appreciate what a few months means to small biotechnology companies; their ability to clean and see the data sooner allows them to get their therapies to the next level and this is always paramount.”
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.